Successful ongoing retreatment with glecaprevir/pibrentasvir + sofosbuvir + ribavirin in a patient with HCV genotype 3 who failed glecaprevir/pibrentasvir with both NS3 and NS5A resistance.
作者信息
Aragri M, Milana M, Di Maio V C, Lenci I, Carioti L, Perno C F, Svicher V, Angelico M, Ceccherini-Silberstein F
机构信息
Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy.
Hepatology Unit, University Hospital of Rome Tor Vergata, Rome, Italy.
出版信息
Clin Microbiol Infect. 2020 Sep;26(9):1266-1268. doi: 10.1016/j.cmi.2020.03.022. Epub 2020 Mar 30.
PMID:32240711
Abstract
摘要
Zotero 插件